Customers Bancorp hit with Fed action for risk management deficiencies By Reuters
By Pete Schroeder
WASHINGTON (Reuters) – The U.S. Federal Reserve announced Thursday it had imposed an enforcement action against Customers Bancorp (NYSE:) for “significant deficiencies” around the bank’s risk management and anti money-laundering practices.
The bank’s stock fell sharply after the Fed announced the action, falling over 20% in midday trading.
The enforcement action against the Pennsylvania-based bank, which provides digital asset services and a tokenized instant payments platform, stemmed from a recent examination by the Fed, the central bank said.
A spokesperson for the bank did not immediately respond to a request for comment.
The enforcement action does not come with a fine, but directs the bank to overhaul its policies to address identified shortcomings, and regularly report back to regulators on its progress.
The order specifically directs the bank to overhaul its risk management around its digital assets business, including ensuring staff have the necessary expertise and sufficient resources, and taking steps to quickly address risk exposures that emerge from that business.
The Fed also directed the bank to bolster its customer due-diligence and suspicious activity reporting.
You Might Also Like
Sempra Energy stock hits 52-week high at $84.28 amid robust growth By Investing.com
Sempra Energy (NYSE:) stock has reached a new 52-week high, touching $84.28, as the company continues to exhibit strong performance....
No change to US policy on long-range missiles to Ukraine expected Friday, White House says By Reuters
By Doina Chiacu WASHINGTON (Reuters) - The United States is not planning to announce any new policy on Ukraine and...
Morgan Stanley expects mergers, IPOs to lag trends through 2024 By Reuters
By Tatiana Bautzer and Arasu Kannagi Basil NEW YORK (Reuters) -Morgan Stanley expects activity for mergers, acquisitions and initial public...
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients12...